☰

ActivCell Group AG

A global veterinary device fleet

A German company making cold plasma therapy systems distributed across 110 countries, transitioning through EU MDR compliance

Industry
Veterinary Medical Devices
Headquarters
Germany
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of ActivCell Group AG's published strategy and is not endorsed by, or produced in cooperation with, ActivCell Group AG. Company website

Strategic priorities

ActivCell Group is a German veterinary medical device company manufacturing cold plasma therapy systems — the ActivCellpen, EquCellpen, and PetCellpen — for the treatment of infected skin diseases and chronic wounds in animals. The company's flagship product, the CAP (Cold Atmospheric Plasma) ActivCellpen, achieved CE certification in July 2023 under MDR regulations, and the company distributes through LIVISTO across 110 countries including recent territorial expansions into the UK, Ireland, Portugal, UAE, and Poland. The company acquired Viormed in 2024, absorbing a Human Medicine division that is in early market entry preparation alongside the commercially active Veterinary Division.

The core digital challenge is the global device fleet: ActivCell has no centralised visibility into the performance, usage patterns, or maintenance needs of the 110-country device fleet. Each regional distributor manages device data locally, and headquarters receives reports retrospectively — preventing predictive maintenance, accurate electrode consumption forecasting, and real-time compliance monitoring. Meanwhile, the transition to full MDR compliance requires continuous clinical evaluation and post-market surveillance that the paper-based QMS cannot support at scale.

The company is led by its CEO and operates a Centre of Excellence model for plasma medicine — using clinical education and KOL engagement to position cold plasma therapy as a standard veterinary treatment rather than an experimental option. The company's Steel Core Electrode launched in 2025, addressing the glass electrode safety hazard that limited adoption in equine medicine.

Challenges we see

  • Digital Integration

    Global device fleet generating no centralised data

    ActivCell's 110-country device fleet — ActivCellpen, EquCellpen, and PetCellpen — operates with no centralised data platform. Each regional distributor manages device data locally using their own tools, and headquarters receives aggregated reports retrospectively rather than real-time operational data.

    When headquarters has no real-time visibility into device usage, maintenance status, or regional adoption patterns, the strategic decisions about product development, electrode supply chain, and distributor support are made without data — the global scale of the operation outpaces the information infrastructure designed to manage it.

  • Regulatory Compliance

    MDR compliance requiring continuous post-market surveillance

    The transition from MDD to MDR has fundamentally altered the regulatory landscape — requiring continuous clinical evaluation, systematic post-market surveillance, and digital QMS rather than the annual review model that MDD allowed. Paper-based quality records cannot support the real-time evidence generation that MDR demands.

    When a post-market surveillance report reveals a device performance issue, the paper-based QMS cannot generate the trend data or incident analysis that MDR requires in the timeframe regulators specify — the CE mark is at risk of suspension if surveillance evidence is not proactively compiled.

  • Manufacturing Safety

    Glass electrode safety hazards limiting equine medicine adoption

    The glass electrodes essential for cold plasma delivery are inherently fragile and pose severe safety hazards during treatment of unpredictable animals, particularly in equine medicine. The legacy fleet of glass-based devices creates ongoing safety incidents that damage brand reputation and limit the addressable market.

    When a glass electrode breaks during equine treatment, the safety incident creates liability exposure, damages the practitioner relationship, and generates negative word-of-mouth in a market where the company's reputation for reliability is still being established.

  • Market Adoption Educational

    Professional resistance to cold plasma therapy in veterinary practice

    Veterinary practitioners maintain deep-seated cultural reliance on antibiotics and traditional treatment protocols despite clinical evidence showing CAP equivalence to standard antimicrobial regimens. Without pervasive changes in clinical guidelines and health insurer reimbursement policies, adoption rates remain below the projections that justify the company's growth strategy.

    When a veterinary practice treats a cold plasma patient unsuccessfully because the treatment protocol was not correctly executed, the failure is attributed to cold plasma therapy rather than to protocol deviation — the adoption curve is slowed by the compounding effect of early adoption errors.

  • Organisational Financial

    Post-Viormed acquisition creating dual-division complexity

    The Viormed acquisition brought a Human Medicine division that is in early market entry preparation while the Veterinary Division drives active commercial expansion. The company lacks IP ownership for all products and relies on exclusive distribution rights for blockbuster products — creating structural vulnerabilities if IP ownership or distribution rights are challenged.

    When distribution rights for a key product are contested, the company's ability to generate revenue from that product is immediately at risk — the absence of IP ownership means the company is dependent on relationships rather than on property rights.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Real-time device KPI platform for the global cold plasma fleet

    ActivCell has no centralised visibility into device health, usage frequency, or regional therapeutic trends across the 110-country fleet. Regional distributors have more data than headquarters, preventing predictive maintenance, accurate electrode consumption forecasting, and real-time compliance monitoring.

    Deploy an IoT-connected device monitoring platform that captures usage patterns, maintenance indicators, and clinical outcome summaries from every ActivCellpen, EquCellpen, and PetCellpen globally — giving headquarters the real-time operational intelligence required to manage a global device fleet.

    • ActivCell Group global device fleet assessment and distributor data audit
    • Current device fleet management and electrode consumption reporting

  2. Paperless QMS and MDR compliance automation

    The transition to MDR requires continuous clinical evaluation and post-market surveillance documentation that paper-based QMS cannot generate at scale. Every regulatory submission, incident report, and clinical evaluation update must be compiled from records that are currently maintained manually — creating compliance risk and administrative overhead.

    Digitalise the QMS with electronic document control, automated post-market surveillance reporting, and GxP-compliant record management — reducing the compliance overhead of MDR while ensuring that all evidence required for regulatory submissions is captured automatically.

    • ActivCell Group MDR compliance gap assessment
    • Current QMS documentation and post-market surveillance process audit

  3. Digital twin R&D for next-generation cold plasma applicators

    Developing specialised electrodes for new applications — ear canal treatment, respiratory therapy with PulmoPlas — requires extensive physical prototyping and testing cycles that consume engineering time and delay time-to-market for new indications.

    Deploy digital twin simulation to model plasma-tissue interactions and test electrode geometries virtually before physical manufacturing — reducing physical prototype iterations and accelerating time-to-market for specialised cold plasma applicators.

    • ActivCell Group electrode R&D pipeline and prototype cycle analysis
    • Current physical prototyping vs virtual simulation capability assessment

  4. AR-based clinical training platform for global distributor network

    Scaling clinical education across 110 countries through physical congresses and webinars creates inconsistent practitioner competency and slow adoption rates. The Centre of Excellence model cannot scale geographically without a digital delivery mechanism for clinical training.

    Deploy an AR/VR-based immersive training platform that standardises clinical education globally — enabling practitioners to learn CAP therapy techniques in virtual environments before patient application, and providing ActivCell with a scalable mechanism for the global roll-out of new treatment protocols.

    • ActivCell Group clinical education programme and distributor training assessment
    • Current physical congress and webinar delivery model scalability analysis

  5. Predictive consumables supply chain for the Razor-Blade model

    The Razor-Blade business model depends on recurring revenue from disposable spacers and specialised electrodes. Inventory is managed via traditional vendor reports without predictive demand forecasting — creating stockout risk for high-margin disposables in fast-growing markets.

    Implement predictive demand analytics integrated with the device monitoring platform — forecasting electrode consumption by market, optimising distributor inventory allocation, and preventing stockouts that would interrupt treatment delivery.

    • ActivCell Group consumables revenue model and distributor inventory assessment
    • Current electrode ordering and stockout frequency analysis

What we'd propose

  • Enterprise AI

    Global IoT Device Monitoring Platform

    We deploy an IoT-connected monitoring platform for ActivCell's global cold plasma device fleet — real-time usage dashboards, predictive maintenance alerts, and regional adoption analytics that give headquarters the operational intelligence to manage 110-country device fleet performance.

    • IoT connectivity and device telemetry for all ActivCellpen models

      Every device connected with real-time usage and health data

      Deploy IoT gateway retrofitting for the ActivCellpen, EquCellpen, and PetCellpen devices — connecting device telemetry to the central platform without requiring full hardware replacement, providing real-time usage counts, power-on hours, and treatment parameters from every device globally.

    • Predictive maintenance alerting by region and distributor

      Maintenance needs predicted before devices fail in the field

      Build predictive maintenance models trained on historical device failure patterns — alerting the regional service team before a device fails in a clinical setting, reducing emergency repair visits and device downtime that interrupts treatment schedules.

    • Regional adoption analytics dashboard

      Treatment volumes and clinical outcomes by country on one screen

      Deploy an adoption analytics dashboard that shows treatment volumes, clinical outcome summaries, and device utilisation rates by country and distributor — giving ActivCell headquarters the visibility to identify high-performing markets and markets where additional clinical training would have the greatest impact.

    • Headquarters has the real-time data to make informed decisions about distributor support, electrode supply allocation, and new market entry timing — the global scale of the operation is managed with the same data quality as a single-country business.
    • Predictive maintenance reduces device downtime in clinical settings — veterinarians experience fewer interrupted treatments, and the ActivCell brand reputation for reliability is strengthened in markets where service responsiveness is a competitive differentiator.
    • The electrode consumption forecast enables proactive inventory positioning — distributor stockouts of high-margin disposables are prevented, protecting both the recurring revenue stream and the treatment continuity for end-use animals.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Paperless QMS and MDR Compliance Automation

    We digitalise ActivCell Group's quality management system with electronic document control, automated post-market surveillance reporting, and GxP-compliant electronic signatures — ensuring that the ActivCellpen maintains its CE mark under MDR scrutiny while reducing the administrative overhead of compliance.

    • Electronic document control with change audit trails

      Every quality document version-tracked and attributable

      Implement electronic document control for all QMS records — design specifications, manufacturing procedures, post-market surveillance reports — with full version history, change attribution, and electronic signatures that meet MDR and ISO 13485 requirements.

    • Automated post-market surveillance reporting

      MDR要求的定期 safety reports generated automatically

      Build automated pipelines that compile incident data, complaint trends, and clinical evaluation updates into the periodic safety report format that MDR requires — reducing the manual effort of compliance reporting and ensuring that reports are submitted on time.

    • CAPA and incident management workflow

      Complaints managed in the QMS, not in email threads

      Configure automated CAPA and incident management workflows — each complaint or adverse event is logged, assigned, investigated, and closed with full traceability, replacing the email-based tracking that creates compliance gaps.

    • The CE mark is protected because the post-market surveillance system generates the evidence regulators require — the MDR compliance posture is proactively maintained rather than retrospectively assembled before an audit.
    • The administrative overhead of QMS compliance is reduced — the quality team spends less time compiling reports and more time on activities that improve product quality rather than documenting it.
    • The electronic QMS accelerates the Human Medicine division's market entry by demonstrating regulatory-grade quality practices to institutional customers and regulatory bodies in new markets.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Digital Twin Platform for Cold Plasma R&D

    We build a digital twin simulation platform for ActivCell's electrode and applicator development — virtual testing of plasma-tissue interactions and electrode geometries before physical prototyping, reducing development cycles and accelerating time-to-market for new cold plasma indications including PulmoPlas respiratory therapy.

    • Plasma-tissue interaction simulation

      Virtual testing of electrode geometries against tissue models

      Build computational models of plasma-tissue interactions for the key therapeutic applications — skin wounds, ear canal treatment, respiratory epithelium — enabling virtual electrode geometry optimisation before physical prototyping begins.

    • Digital prototype validation and iteration

      Electrode designs tested in simulation before manufacturing

      Configure the digital twin platform for rapid design iteration — engineers test geometry changes in simulation, identify failure modes virtually, and converge on an optimised design with fewer physical prototype cycles.

    • Regulatory submission package from simulation data

      Simulation reports included in new indication regulatory filings

      Build the regulatory submission package framework that incorporates digital twin validation data — enabling virtual testing results to support new indication filings with regulators who accept in-silico evidence alongside clinical data.

    • Time-to-market for new cold plasma indications is reduced because physical prototype iterations are replaced by virtual testing cycles — the PulmoPlas respiratory therapy and ear canal applicator reach clinical use months faster.
    • Engineering time is focused on innovation rather than iterative testing — the team's capacity is directed toward novel electrode designs rather than repeating the same physical test protocol for each geometry variation.
    • The digital twin platform provides evidence for regulatory submissions in markets that accept in-silico validation — the regulatory burden for new indications is reduced by the portion of testing that is performed virtually.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Immersive AR/VR Clinical Training Platform

    We deploy an AR/VR-based immersive training platform for ActivCell's global distributor network and veterinary practitioner base — standardised CAP therapy education delivered through virtual environments that allow practitioners to build competency before treating animals, accelerating adoption in new markets.

    • VR CAP therapy procedure training modules

      Veterinarians trained in virtual environments before patient treatment

      Develop VR training modules for the key CAP therapy protocols — wound treatment, chronic skin disease, equine medicine — allowing veterinarians to practice electrode positioning, treatment duration, and follow-up protocols in a virtual setting.

    • AR-assisted real-time treatment guidance

      AR overlays guide practitioners through treatment protocols

      Build AR-assisted treatment guidance that overlays electrode positioning cues and treatment parameters onto the practitioner's view during actual patient treatment — reducing protocol deviations that lead to suboptimal outcomes.

    • Global training completion and competency tracking

      Training compliance tracked by distributor and region

      Configure training completion tracking that gives ActivCell and distributors visibility into practitioner certification status — ensuring that only trained practitioners are prescribing and delivering CAP therapy in each market.

    • Clinical adoption accelerates because practitioners are competent before they attempt their first patient treatment — the early-adoption error rate that slows market penetration is reduced by structured VR training.
    • The Centre of Excellence model scales geographically without proportional investment in physical training infrastructure — new markets can be entered with digital training delivery rather than requiring an in-person training programme.
    • AR-assisted treatment guidance reduces protocol deviations in live treatments — the clinical outcomes improve as practitioners follow correct electrode positioning and treatment duration protocols.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Predictive Consumables Supply Chain Platform

    We implement predictive demand analytics for ActivCell's Razor-Blade consumables model — electrode and spacer demand forecasting by market, distributor inventory optimisation, and automated replenishment triggers that prevent stockouts across the 110-country distribution network.

    • Electrode consumption forecasting by region and product line

      Demand predicted by country, distributor, and device model

      Build demand forecasting models trained on historical electrode consumption, seasonal treatment patterns, and new distributor onboarding — predicting electrode demand by market and device model months in advance to enable proactive inventory positioning.

    • Distributor inventory optimisation and reorder automation

      Distributor stock levels optimised against forecasted demand

      Deploy distributor inventory optimisation that recommends reorder timing and quantities based on forecasted demand, current stock levels, and delivery lead times — preventing both stockouts and overstocking across the distribution network.

    • Supply chain risk alerting for critical components

      Supply disruptions for electrode components identified early

      Configure supply chain risk alerting that monitors component supplier capacity for the electrode and spacer supply chain — flagging when a supplier capacity constraint would impact delivery schedules before the constraint becomes a stockout.

    • Distributor stockouts of high-margin electrodes are prevented because demand is forecasted and replenishment is triggered automatically — the recurring revenue stream is protected and veterinarians can access CAP therapy treatments without supply interruptions.
    • Inventory holding costs are reduced because distributors maintain optimal stock levels rather than defaulting to high safety stock — the working capital tied up in electrode inventory is freed for other investments.
    • The supply chain visibility platform enables ActivCell to identify which markets are growing fastest — the commercial team can prioritise distributor relationships and support investment based on actual treatment volume data.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what ActivCell Group AG's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Regulatory Data Integrity 45 → 95
The MDR transition requires continuous post-market surveillance and electronic QMS records. The current paper-based QMS cannot generate the trend data, incident analysis, or periodic safety reports that MDR regulators require. The digital QMS required for MDR compliance has not been implemented.
Fleet IoT Connectivity 10 → 85
The 110-country device fleet operates with no centralised data platform. Regional distributors manage device data locally with no real-time connectivity to headquarters. The IoT gateway retrofitting and device monitoring platform required to connect the global fleet has not been deployed.
Supply Chain Prediction 20 → 80
Electrode and spacer demand is managed via distributor self-reporting without predictive forecasting. No demand analytics or inventory optimisation exists. The Razor-Blade recurring revenue is vulnerable to distributor stockouts caused by demand forecasting failures.
R&D Digital Twin 15 → 90
Electrode development relies on physical prototyping and iterative testing. No digital simulation capability exists for plasma-tissue interaction modelling. The digital twin platform required for accelerated applicator development has not been built.
IT/OT Interoperability 30 → 85
The gap between the device fleet OT layer and enterprise IT systems prevents real-time data flow. No standardised IoT connectivity or data platform unifies the global device operations. The integration architecture required to connect the fleet has not been designed.
Training Digitisation 40 → 85
Clinical education relies on physical congresses, webinars, and informal distributor training. No immersive AR/VR training platform exists. The Centre of Excellence model cannot scale geographically without digital training delivery mechanisms.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with ActivCell Group AG, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].